Lieven Baert

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. ncbi Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment
    Lieven Baert
    Tibotec BVBA, Gen De Wittelaan L11B 3, 2800 Mechelen, Belgium
    Eur J Pharm Biopharm 72:502-8. 2009
  2. ncbi Development of an implantable infusion pump for sustained anti-HIV drug administration
    Lieven Baert
    Chem Pharm Development, Tibotec BVBA, Gen De Wittelaan L11B 3, BE 2800 Mechelen, Belgium
    Int J Pharm 355:38-44. 2008
  3. ncbi Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation
    Gerben van 't Klooster
    Tibotec BVBA, Mechelen, Belgium
    Antimicrob Agents Chemother 54:2042-50. 2010
  4. ncbi Dog model with implanted pump to test boosters for antiretroviral medication
    Laurent Schueller
    Chem Pharm Development, Tibotec BVBA, Gen De Wittelaan L11B 3, 2800 Mechelen, Belgium
    Int J Pharm 355:45-52. 2008

Collaborators

Detail Information

Publications4

  1. ncbi Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment
    Lieven Baert
    Tibotec BVBA, Gen De Wittelaan L11B 3, 2800 Mechelen, Belgium
    Eur J Pharm Biopharm 72:502-8. 2009
    ..In conclusion, this study provides proof-of-concept that 200-nm sized TMC278 nanosuspensions may act as long-acting injectable...
  2. ncbi Development of an implantable infusion pump for sustained anti-HIV drug administration
    Lieven Baert
    Chem Pharm Development, Tibotec BVBA, Gen De Wittelaan L11B 3, BE 2800 Mechelen, Belgium
    Int J Pharm 355:38-44. 2008
    ....
  3. ncbi Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation
    Gerben van 't Klooster
    Tibotec BVBA, Mechelen, Belgium
    Antimicrob Agents Chemother 54:2042-50. 2010
    ..The findings support clinical investigations of rilpivirine nanosuspension as a long-acting formulation to improve adherence during antiretroviral therapy and for preexposure prophylaxis...
  4. ncbi Dog model with implanted pump to test boosters for antiretroviral medication
    Laurent Schueller
    Chem Pharm Development, Tibotec BVBA, Gen De Wittelaan L11B 3, 2800 Mechelen, Belgium
    Int J Pharm 355:45-52. 2008
    ....